MD Anderson study predicts new hepatitis C drugs will place a dramatic financial strain on the health care system

This study was finalized prior to FDA approval of
AbbVie's HCV drug, and of Gilead's announcement that discounts on
Sovaldi would be discounted up to 46 percent on average. In subsequent
analysis using older discounts for 2014 and then applying the 46 percent
discount for 2015 onward, Dr. Chhatwal predicts the budget needed would
be $90 billion over five years (versus $136 billion). Compared with old
drugs, new therapies would cost an additional $20 billion (versus $65
billion), with $16 billion in cost offsets. 

Source: M. D. Anderson Cancer Center - News Releases - March 16, 2015 Category: Cancer & Oncology Source Type: news